Inclusion body myositis (IBM) and polymyositis can normally be distinguished on the basis of clinical features. However, patients with an atypical disease presentation, particularly those with early-stage disease, can be challenging to diagnose. Can imaging with amyloid-PET help distinguish these two diseases?
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Greenberg, S. A. Inclusion body myositis: clinical features and pathogenesis. Nat. Rev. Rheumatol. https://doi.org/10.1038/s41584-019-0186-x (2019).
Lilleker, J. B. et al. [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann. Rheum. Dis. 78, 657–662 (2019).
Chahin, N. & Engel, A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70, 418–424 (2008).
Pruitt, J. N. 2nd, Showalter, C. J. & Engel, A. G. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann. Neurol. 39, 139–143 (1996).
Wong, D. F. et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51, 913–920 (2010).
Sherriff, F. E. et al. Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not beta-amyloid. Neurosci. Lett. 194, 37–40 (1995).
Park, M. A. et al. 18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ. Cardiovasc. Imaging 8, e002954 (2015).
Pinal-Fernandez, I. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann. Rheum. Dis. 76, 681–687 (2017).
Tasca, G. et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 52, 956–962 (2015).
Lloyd, T. E. et al. Cytosolic 5′-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res. 68, 66–71 (2016).
The authors declare no competing interests.
About this article
Cite this article
Pinal-Fernandez, I., Mammen, A.L. Amyloid-PET: a new tool for diagnosing IBM?. Nat Rev Rheumatol 15, 321–322 (2019). https://doi.org/10.1038/s41584-019-0223-9
This article is cited by
Current Rheumatology Reports (2019)